Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

33results about How to "Avoid systemic side effects" patented technology

Atropine eyewater in low concentration for restraining increase of degree of short sight and preparing method

InactiveCN101049287AImprove pupil dilationImprove photophobia and other side effectsSenses disorderPharmaceutical delivery mechanismMedicineUltraviolet
A low-concentration atropine as eye medicine for treating myopia, cataract, retinosis, etc is disclosed. Its advantages are not afraid of light and high suppleness.
Owner:CHANG GUNG MEMORIAL HOSPITAL

Fc-region variants with modified fcrn-binding properties

Herein is reported a polypeptide comprising a first polypeptide and a second polypeptide each comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, whereini) the first and the second polypeptide comprise the mutations H310A, H433A and Y436A, orii) the first and the second polypeptide comprise the mutations L251D, L314D and L432D, oriii) the first and the second polypeptide comprise the mutations L251S, L314S and L432S.
Owner:F HOFFMANN LA ROCHE & CO AG

"methods and products for treatment of diseases"

The present invention relates to the treatment of diseases and conditions with an effective amount of a steroid having those formulas given in the specification, or a pharmacologically-acceptable salt or ester thereof. The disease or conditions treatable according to the invention include angiogenic diseases and conditions of the eye, angiogenic diseases and conditions of the brain, inflammatory diseases and conditions of the eye, inflammatory diseases and conditions of the brain and neurodegenerative diseases.
Owner:AMPIO PHARMA

Fc-region variants with modified fcrn- and protein a-binding properties

Herein is reported a heterodimeric polypeptide comprising a first polypeptide comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, and a second polypeptide comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, wherein the first polypeptide comprises the mutations Y349C, T366S, L368A and Y407V (hole-chain) and the second polypeptide comprises the mutations S354C and T366W (knob-chain), and wherein the first polypeptide (hole-chain) comprises the mutations i) I253A or I253G, and ii) L314A or L314G or L314D, and wherein the first polypeptide and the second polypeptide are connected by one or more disulfide bridges, and wherein the CH3-domain of the first polypeptide and the CH3-domain of the second polypeptide both bind or both do not bind to protein A (numbering according to the Kabat EU index).
Owner:F HOFFMANN LA ROCHE & CO AG

Compositions and Methods of Topical Drug Delivery for the Treatment of Carpal Tunnel Syndrome

The present invention generally relates to transdermal drug delivery systems. More particularly, the present invention provides compositions and transdermal drug delivery systems for the treatment and / or relief of symptoms associated with carpal tunnel syndrome or tendonitis.
Owner:MSK PHARMA

Gastric targeted drug carrier and preparation method thereof

The invention relates to the field of drug carrier preparation, in particular to a gastric targeted drug carrier and a preparation method thereof. The gastric targeted drug carrier is prepared from the following raw materials: drug-containing emulsion and a crosslinking agent, wherein the drug-containing emulsion contains chitosan, chitosan quaternary ammonium salt and sodium glycerophosphate; and the crosslinking agent is used for crosslinking the emulsion into microspheres. The preparation method comprises the following steps: 1) preparing the drug-containing emulsion: with a aqueous solution of chitosan, chitosan quaternary ammonium salt and sodium glycerophosphate as an aqueous phase W, preparing the drug-containing emulsion with the aqueous phase, drugs and an oil phase containing anemulsifying agent; and 2) heating and stirring the drug-containing emulsion prepared in the step 1), crosslinking the chitosan quaternary ammonium salt and sodium glycerophosphate contained in the drug-containing emulsion to obtain gel microsphere suspension, heating the suspension and adding the crosslinking agent to carry out secondary crosslinking to solidify the gel microspheres. The drug carrier has the advantages of uniform and controllable grain size, high embedding rate and good dispersibility and simultaneously meets the requirements of the gastric targeted drug delivery carrier.
Owner:INST OF PROCESS ENG CHINESE ACAD OF SCI

Fluticasone propionate foaming agent composition

InactiveCN101926765AConvenient treatmentOvercomes the drawbacks of being unsuitable for the treatment of ulcerative colitisOrganic active ingredientsAerosol deliveryFoaming agentFluticasone propionate
The invention discloses a fluticasone propionate foaming agent composition, which contains fluticasone propionate serving as an active ingredient and one or more pharmaceutically acceptable auxiliary materials for a foaming agent, wherein the content of the fluticasone propionate serving as the active ingredient is 0.05 to 0.2 percent (weight / weight), and the volume expansion ratio of the foaming agent composition is 25 to 50.
Owner:TIANJIN JINYAO GRP

Instillation of liposomal formulation of sirna and antisense oligonucleotides

A pharmaceutically acceptable deliverable composition and methods for administration of macromolecules for sequence-specific gene-silencing in bladder to treat overactive bladder (OAB), interstitial cystitis / painful bladder syndrome (IC / PBS), lower urinary tract symptoms (LUTS) locally in the bladder, or other diseases or disorders of the bladder or LUTS, has been discovered. In the preferred embodiment, a liposome based delivery system is used to deliver an effective amount of antisense oligonucleotides (ODN) or siRNA that interact with or bind to messenger RNA (mRNA) coding for human nerve growth factor (NGF) to stop the synthesis of NGF.
Owner:LIPELLA PHARMA

Antimicrobial medicament preparation with polyanhydrides as vector and its preparing process

The invention relates to an anti-microbe drug which uses poly acid anhydride as carrier. The invention uses poly acid anhydride (as fatty group poly acid anhydride, aromatic nucleus poly acid anhydride, phosphor poly acid anhydride, polyamide poly acid anhydride, polyester poly acid anhydride or the like or their polymer) as carrier to be mixed via the drug, to be heated and fused into biological degradable slow-release agent. The inventive agent can be prepared into disc and rod shapes via mould according to the clinic demands. And the external degradation test has proved that the drug can reach zero-level release, without instant-release effect, to realize the slow-release object and confirm the safety.
Owner:HEBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY

Fc-region variants with modified fcrn- and protein a-binding properties

Herein is reported a heterodimeric polypeptide comprising a first polypeptide comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, and a second polypeptide comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, wherein the first polypeptide comprises the mutations Y349C, T366S, L368A and Y407V (hole-chain) and the second polypeptide comprises the mutations S354C and T366W (knob-chain), and wherein the first polypeptide (hole-chain) comprises the mutations i) I253A or I253G, and ii) L314A or L314G or L314D, and wherein the first polypeptide and the second polypeptide are connected by one or more disulfide bridges, and wherein the CH3-domain of the first polypeptide and the CH3-domain of the second polypeptide both bind or both do not bind to protein A (numbering according to the Kabat EU index).
Owner:F HOFFMANN LA ROCHE INC

Anti-inflammatory fusion protein

The present invention relates to a fusion protein comprising therapeutical and diagnostic potential against chronic vascular diseases, such as atherosclerosis, a nucleic acid molecule encoding said fusion protein, a pharmaceutical and diagnostic composition which comprises the fusion protein or the nucleic acid molecule, the use of the fusion protein or the nucleic acid molecule for the production of a pharmaceutical and diagnostic composition, a method for the diagnosis of acute or chronic vascular diseases, and a method for the production of a fusion protein.
Owner:UNIV TUBINGEN

Gastric targeted drug carrier and preparation method thereof

The invention relates to the field of drug carrier preparation, in particular to a gastric targeted drug carrier and a preparation method thereof. The gastric targeted drug carrier is prepared from the following raw materials: drug-containing emulsion and a crosslinking agent, wherein the drug-containing emulsion contains chitosan, chitosan quaternary ammonium salt and sodium glycerophosphate; and the crosslinking agent is used for crosslinking the emulsion into microspheres. The preparation method comprises the following steps: 1) preparing the drug-containing emulsion: with a aqueous solution of chitosan, chitosan quaternary ammonium salt and sodium glycerophosphate as an aqueous phase W, preparing the drug-containing emulsion with the aqueous phase, drugs and an oil phase containing anemulsifying agent; and 2) heating and stirring the drug-containing emulsion prepared in the step 1), crosslinking the chitosan quaternary ammonium salt and sodium glycerophosphate contained in the drug-containing emulsion to obtain gel microsphere suspension, heating the suspension and adding the crosslinking agent to carry out secondary crosslinking to solidify the gel microspheres. The drug carrier has the advantages of uniform and controllable grain size, high embedding rate and good dispersibility and simultaneously meets the requirements of the gastric targeted drug delivery carrier.
Owner:INST OF PROCESS ENG CHINESE ACAD OF SCI

Tofacitinib nanocrystal eye drops and preparation method thereof

The invention provides tofacitinib nanocrystal eye drops for treating immunity-related eye diseases and a preparation method thereof, and the tofacitinib nanocrystal eye drops are prepared by the following steps: dispersing micronized tofacitinib in a surfactant solution at a high speed, then mixing with a stabilizer, uniformly dispersing, and then carrying out high-pressure homogenization circulation, so as to obtain the tofacitinib nanocrystal eye drops. The tofacitinib nanocrystal eye drops meeting the particle size requirement are obtained. Wherein the surfactant is P188-lecithin, and the stabilizer is any one or a mixture of more of HPMC (Hydroxy Propyl Methyl Cellulose), polyvinyl alcohol and HPMC-docusate sodium. Through cooperation of the surfactant and the stabilizer, the particle size and the potential of the eye drops are influenced, the stability and the adhesiveness are improved, the residence time of the medicine in eyes is prolonged, and the medicine carrying rate is high. The loss speed of the medicine in front of the cornea is reduced, so that the medicine can be slowly released, the eye drop frequency of a patient is reduced, the compliance of the patient is improved, and a good clinical application prospect is achieved.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV

Pharmaceutical composition of olopatadine or salts of olopatadine, and preparation method thereof

The invention discloses a pharmaceutical composition of olopatadine or salts of olopatadine for treating allergic conjunctivitis, and a preparation method thereof. The composition mainly comprises the olopatadine or the salts of the olopatadine, and polycarbophil or polycarbophil salt or carbomer. The preparation method comprises firstly fully swelling the polycarbophil or the polycarbophil salt or the carbomer with a proper amount of pure water, and secondly adding the olopatadine or the salts of the olopatadine and other accessories.
Owner:JIANGSU YABANG AIPUSEN PHARMA

Method of treating viral infections

A method of pharmaceutical therapy comprising the co-administration of any form of interferon or any derivative thereof with a low dose of ribavirin (less than 400 mg / day or less than 6 mg / kg / day), or related compound, where the ribavirin or related compound provides a clinically effective blood level in the portal circulation but a less than clinically effective blood level in the peripheral circulation, to thereby provide a systemic effect of interferon throughout the body but a selective effect of ribavirin in the liver. The method also provides for the co-administration of any form of interferon or any derivative thereof with a high dose of ribavirin (preferably from 400-800 mg / day), or related compound, where the ribavirin or related compound is administered as a slow-release formulation such that it also provides a sustained virologic response in a patient and reduced side effects. The method also provides for the co-administration of an antioxidant or other membrane protective agent with both the interferon and ribavirin such that the hepatoprotective activity of the antioxidant or other membrane protective agent complements the virucidal effect of the interferon and ribavirin. The antioxidant or other membrane protective agent may be administered as a systemic or a low-dose, slow-release, liver-selective formulation.
Owner:HOWARD J SMITH & ASSOC

Application of hollow nano-particles in preparation of medicine for treating osteoporosis

The invention discloses application of hollow nano-particles in preparation of a medicine for treating osteoporosis, and belongs to the technical field of medical medicine preparation. Firstly, the invention provides the application of the hollow nano-particles which take extracorporeal shock wave response type zoledronic acid as a skeleton ingredient in the preparation of the medicine for treating the osteoporosis. Secondly, the invention provides the application of the hollow nano-particles which take zoledronic acid and / or a composition containing the zoledronic acid as the skeleton ingredient in the preparation of the medicine for treating the osteoporosis, in the application, an extracorporeal shock wave is adopted to carry out intervention on the hollow nano-particles, and specifically, the extracorporeal shock wave is used for carrying out local in-situ breaking on the hollow nano-particles so as to perform an obvious osteoporosis treatment effect. The shell thickness of a hollow nano-hydroxyapatite particle is controlled, the responsiveness of the extracorporeal shock wave of the particle can be enhanced, local release control is realized, the particles can be broken in a specific bone zone, local bone density is improved, and an osteoporosis treatment purpose is performed.
Owner:THE THIRD MEDICAL CENT OF THE CHINESE PEOPLES LIBERATION ARMY GENERAL HOSPITAL

Use of an antimicrobial composition

The invention concerns the use of an antimicrobial composition comprising metallic silver and metallic ruthenium as well as at least one vitamin or at least one vitamin derivative for the topical treatment or prevention of skin, skin adnexa or mucosa diseases which are caused by infection with at least one microorganism. The invention also concerns a bandaging material or patch comprising an antimicrobial composition which comprises metallic silver and metallic ruthenium as well as at least one vitamin or at least one vitamin derivative. The antimicrobial composition (“AgXX”) has a broad-spectrum effect against bacteria (a: E. coli) and fungi (b: Pathogen is yeast and c: Penicillium).a) Escherichia coli (additionally silver (“Ag”) as control),b) Candida parapsilosis, c) Penicillium notatum;
Owner:AGXX INTPROP HLDG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products